Published in Atten Defic Hyperact Disord on September 23, 2009
Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD. Clin Pharmacol Ther (2016) 0.79
Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol (2014) 0.77
Efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in patients with common comorbidities in children, adolescents and adults: a review. Ther Adv Psychopharmacol (2016) 0.76
A critical appraisal of atomoxetine in the management of ADHD. Ther Clin Risk Manag (2015) 0.76
Cardiovascular side effects of atomoxetine and its interactions with inhibitors of the cytochrome p450 system. Case Rep Med (2011) 0.75
Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry (1997) 41.93
Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry (2001) 3.87
Prevalence and assessment of attention-deficit/hyperactivity disorder in primary care settings. Pediatrics (2001) 2.59
Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet (2005) 1.55
Enhancement of atomoxetine serum levels by co-administration of paroxetine. Int J Neuropsychopharmacol (2007) 1.44
Impact of comorbid oppositional or conduct problems on attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (1997) 1.18
Differences between preschool children with ODD, ADHD, and ODD+ADHD symptoms. J Child Psychol Psychiatry (2002) 1.14
Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S,S)-[18F]FMeNER-D2. Psychopharmacology (Berl) (2006) 1.10
CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry (2007) 1.05
Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. Pediatrics (2008) 1.05
Association between dopamine transporter (DAT1) genotype, left-sided inattention, and an enhanced response to methylphenidate in attention-deficit hyperactivity disorder. Neuropsychopharmacology (2005) 1.02
Methylphenidate blood levels and therapeutic response in children with attention-deficit hyperactivity disorder: I. Effects of different dosing regimens. J Child Adolesc Psychopharmacol (2006) 0.93
ODD and ADHD symptoms in Ukrainian children: external validators and comorbidity. J Am Acad Child Adolesc Psychiatry (2004) 0.90
CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD. Eur Neuropsychopharmacol (2007) 0.89
High-dose atomoxetine treatment of ADHD in youths with limited response to standard doses. J Am Acad Child Adolesc Psychiatry (2007) 0.88
Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. Am J Psychiatry (2013) 5.89
Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet (2009) 3.86
The endophytic fungus Piriformospora indica reprograms barley to salt-stress tolerance, disease resistance, and higher yield. Proc Natl Acad Sci U S A (2005) 2.74
Obstructive sleep apnea and incidence of postoperative delirium after elective knee replacement in the nondemented elderly. Anesthesiology (2012) 2.29
Adaptation of energy metabolism in breast cancer brain metastases. Cancer Res (2007) 2.17
Deletions and epimutations affecting the human 14q32.2 imprinted region in individuals with paternal and maternal upd(14)-like phenotypes. Nat Genet (2008) 2.16
Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry (2007) 2.11
A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain (2005) 2.10
Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res (2010) 2.09
Interacting effects of the dopamine transporter gene and psychosocial adversity on attention-deficit/hyperactivity disorder symptoms among 15-year-olds from a high-risk community sample. Arch Gen Psychiatry (2007) 2.02
A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med (2005) 1.99
The phenotypic spectrum of COL2A1 mutations. Hum Mutat (2005) 1.85
The thioredoxin system--from science to clinic. Med Res Rev (2004) 1.82
Increased frequency of rolandic spikes in ADHD children. Epilepsia (2003) 1.73
A comparison of neuropsychiatric and cognitive profiles in delirium, dementia, comorbid delirium-dementia and cognitively intact controls. J Neurol Neurosurg Psychiatry (2010) 1.72
Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol (2009) 1.70
Duloxetine for the treatment of fibromyalgia in women: pooled results from two randomized, placebo-controlled clinical trials. J Womens Health (Larchmt) (2007) 1.69
On the potential of thioredoxin reductase inhibitors for cancer therapy. Semin Cancer Biol (2006) 1.63
Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. CNS Drugs (2013) 1.58
Murine tumor necrosis factor α-induced adipose-related protein (tumor necrosis factor α-induced protein 9) deficiency leads to arthritis via interleukin-6 overproduction with enhanced NF-κB, STAT-3 signaling, and dysregulated apoptosis of macrophages. Arthritis Rheum (2012) 1.52
High humidity induces abscisic acid 8'-hydroxylase in stomata and vasculature to regulate local and systemic abscisic acid responses in Arabidopsis. Plant Physiol (2008) 1.50
Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs. clozapine. Int J Neuropsychopharmacol (2005) 1.50
Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania. Br J Psychiatry (2004) 1.46
In vitro assessment of methylene blue on chloroquine-sensitive and -resistant Plasmodium falciparum strains reveals synergistic action with artemisinins. Antimicrob Agents Chemother (2005) 1.46
Molecular genetics of attention-deficit/hyperactivity disorder: an overview. Eur Child Adolesc Psychiatry (2010) 1.45
Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study. Br J Psychiatry (2008) 1.40
Methylene blue as an antimalarial agent. Redox Rep (2003) 1.39
Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry (2004) 1.38
Impact of age at first drink on vulnerability to alcohol-related problems: testing the marker hypothesis in a prospective study of young adults. J Psychiatr Res (2009) 1.37
Impact of psychosocial adversity on alcohol intake in young adults: moderation by the LL genotype of the serotonin transporter polymorphism. Biol Psychiatry (2009) 1.37
Delirium in an adult acute hospital population: predictors, prevalence and detection. BMJ Open (2013) 1.37
Phenomenology of delirium. Assessment of 100 adult cases using standardised measures. Br J Psychiatry (2007) 1.36
Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry (2008) 1.35
Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry (2013) 1.29
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum. Antimicrob Agents Chemother (2007) 1.28
Interaction between the 5-HTTLPR serotonin transporter polymorphism and environmental adversity for mood and anxiety psychopathology: evidence from a high-risk community sample of young adults. Int J Neuropsychopharmacol (2009) 1.28
Novelty seeking involved in mediating the association between the dopamine D4 receptor gene exon III polymorphism and heavy drinking in male adolescents: results from a high-risk community sample. Biol Psychiatry (2006) 1.27
Crystal structure of a novel Plasmodium falciparum 1-Cys peroxiredoxin. J Mol Biol (2005) 1.27
Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. Psychoneuroendocrinology (2008) 1.26
Protein-tyrosine phosphatase, nonreceptor type 11 mutation analysis and clinical assessment in 45 patients with Noonan syndrome. J Clin Endocrinol Metab (2004) 1.24
Compartmentation of redox metabolism in malaria parasites. PLoS Pathog (2010) 1.22
Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J Clin Psychiatry (2007) 1.21
The Plasmodium selenoproteome. Nucleic Acids Res (2006) 1.21
Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend (2008) 1.21
A putative glutathione peroxidase of Drosophila encodes a thioredoxin peroxidase that provides resistance against oxidative stress but fails to complement a lack of catalase activity. Biol Chem (2003) 1.20
Crystal structure of the antioxidant enzyme glutathione reductase inactivated by peroxynitrite. J Biol Chem (2001) 1.14
Comparing symptoms of delirium in adults and children. Psychosomatics (2006) 1.14
Glutathione S-transferase of the malarial parasite Plasmodium falciparum: characterization of a potential drug target. Biol Chem (2002) 1.14
Hepatic effects of duloxetine-I: non-clinical and clinical trial data. Curr Drug Saf (2008) 1.13
Mitochondrial and cytoplasmic thioredoxin reductase variants encoded by a single Drosophila gene are both essential for viability. J Biol Chem (2002) 1.12
Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects. J Clin Pharmacol (2014) 1.12
The Drosophila carbonyl reductase sniffer prevents oxidative stress-induced neurodegeneration. Curr Biol (2004) 1.12
Diversity of chemical mechanisms in thioredoxin catalysis revealed by single-molecule force spectroscopy. Nat Struct Mol Biol (2009) 1.11
Thioredoxin networks in the malarial parasite Plasmodium falciparum. Antioxid Redox Signal (2006) 1.10
Genetic variation in dopamine pathways differentially associated with smoking progression in adolescence. J Am Acad Child Adolesc Psychiatry (2008) 1.09
The delirium rating scale in children and adolescents. Psychosomatics (2003) 1.09
Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study. J Clin Psychopharmacol (2007) 1.07
Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder. J Clin Psychopharmacol (2006) 1.07
Large-scale differential proteome analysis in Plasmodium falciparum under drug treatment. PLoS One (2008) 1.07
Association of the DRD4 exon III polymorphism with smoking in fifteen-year-olds: a mediating role for novelty seeking? J Am Acad Child Adolesc Psychiatry (2005) 1.07
Transposon-mediated transgenesis, transgenic rescue, and tissue-specific gene expression in rodents and rabbits. FASEB J (2012) 1.07
Effectiveness of atomoxetine and quality of life in children with attention-deficit/hyperactivity disorder as perceived by patients, parents, and physicians in an open-label study. J Child Adolesc Psychopharmacol (2007) 1.06
A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. Int J Gen Med (2008) 1.06
CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry (2007) 1.05
Validation of the adult ADHD investigator symptom rating scale (AISRS). J Atten Disord (2009) 1.05
Plasmodium falciparum--do killers commit suicide? Trends Parasitol (2004) 1.04
Therapeutic effects of antibodies to tumor necrosis factor-alpha, interleukin-6 and cytotoxic T-lymphocyte antigen 4 immunoglobulin in mice with glucose-6-phosphate isomerase induced arthritis. Arthritis Res Ther (2008) 1.04
Characterization of the glyoxalases of the malarial parasite Plasmodium falciparum and comparison with their human counterparts. Biol Chem (2005) 1.04
Identification and characterization of heme-interacting proteins in the malaria parasite, Plasmodium falciparum. J Biol Chem (2003) 1.03
Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol (2003) 1.03
From nature versus nurture, via nature and nurture, to gene x environment interaction in mental disorders. Eur Child Adolesc Psychiatry (2009) 1.02
Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol (2003) 1.02
The malarial parasite Plasmodium falciparum imports the human protein peroxiredoxin 2 for peroxide detoxification. Proc Natl Acad Sci U S A (2009) 1.02
HIPK2 kinase activity depends on cis-autophosphorylation of its activation loop. J Mol Cell Biol (2012) 1.02
Thioredoxin and glutathione systems in Plasmodium falciparum. Int J Med Microbiol (2012) 1.02
Protein S-glutathionylation in malaria parasites. Antioxid Redox Signal (2011) 1.01
Crystal structure of the human thioredoxin reductase-thioredoxin complex. Nat Commun (2011) 1.01
Internet chat rooms and suicide. J Am Acad Child Adolesc Psychiatry (2004) 1.00
X-ray structure of glutathione S-transferase from the malarial parasite Plasmodium falciparum. Proc Natl Acad Sci U S A (2003) 1.00
The thioredoxin specificity of Drosophila GPx: a paradigm for a peroxiredoxin-like mechanism of many glutathione peroxidases. J Mol Biol (2006) 1.00
Undressing of phosphine gold(I) complexes as irreversible inhibitors of human disulfide reductases. Angew Chem Int Ed Engl (2006) 1.00
The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials. J Clin Psychiatry (2009) 0.99
Molecular pathology of Shprintzen-Goldberg syndrome. Am J Med Genet A (2006) 0.99
Enhanced carbonyl stress in a subpopulation of schizophrenia. Arch Gen Psychiatry (2010) 0.99
Glutathione S-transferase from malarial parasites: structural and functional aspects. Methods Enzymol (2005) 0.98
Emotional well-being in children and adolescents treated with atomoxetine for attention-deficit/hyperactivity disorder: findings from a patient, parent and physician perspective using items from the pediatric adverse event rating scale (PAERS). Child Adolesc Psychiatry Ment Health (2008) 0.98
Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. J Palliat Med (2006) 0.98
Evidence that 5-HT2A receptors in the hypothalamic paraventricular nucleus mediate neuroendocrine responses to (-)DOI. J Neurosci (2002) 0.96
Arthritogenic T cell epitope in glucose-6-phosphate isomerase-induced arthritis. Arthritis Res Ther (2008) 0.96
Plasmodium falciparum glutathione S-transferase--structural and mechanistic studies on ligand binding and enzyme inhibition. Protein Sci (2005) 0.96
Glyoxalase I of the malarial parasite Plasmodium falciparum: evidence for subunit fusion. FEBS Lett (2003) 0.96
Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. Clin Pharmacol Ther (2003) 0.96
Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. Blood (2002) 0.95
Neuropsychological basic deficits in preschoolers at risk for ADHD: a meta-analysis. Clin Psychol Rev (2011) 0.94
Intracellular positioning of isoforms explains an unusually large adenylate kinase gene family in the parasite Trypanosoma brucei. J Biol Chem (2005) 0.94
Comparative structural analysis of oxidized and reduced thioredoxin from Drosophila melanogaster. J Mol Biol (2004) 0.94
High-density oligonucleotide array with sub-kilobase resolution reveals breakpoint information of submicroscopic deletions in nevoid basal cell carcinoma syndrome. Hum Genet (2007) 0.93
An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain. Pain Med (2007) 0.93
Mechanism-based inactivation of thioredoxin reductase from Plasmodium falciparum by Mannich bases. Implication for cytotoxicity. Biochemistry (2003) 0.93
Desensitization of 5-HT1A receptors by 5-HT2A receptors in neuroendocrine neurons in vivo. J Pharmacol Exp Ther (2004) 0.93